Martin Vogelbaum - Jun 2, 2022 Form 4 Insider Report for Cara Therapeutics, Inc. (CARA)

Role
Director
Signature
/s/Darren DeStefano, Attorney-in-Fact
Stock symbol
CARA
Transactions as of
Jun 2, 2022
Transactions value $
$0
Form type
4
Date filed
6/6/2022, 05:49 PM
Previous filing
Jun 7, 2021
Next filing
Sep 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CARA Common Stock Award $0 +23.8K +117.82% $0.00 43.9K Jun 2, 2022 Direct F1
transaction CARA Common Stock Award $0 +11.9K +27.04% $0.00 55.8K Jun 2, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CARA Stock Option (Right to Buy) Award $0 +34K $0.00 34K Jun 2, 2022 Common Stock 34K $8.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
F2 Represents a one-time grant of 11,876 RSUs. Each RSU represents the contingent right to receive one share of the common stock of the Issuer. The RSUs are fully vested on the date of grant.
F3 This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.